Teacher Retirement System of Texas Sells 8,778 Shares of Lantheus Holdings, Inc. $LNTH

Teacher Retirement System of Texas reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.4% in the third quarter, HoldingsChannel reports. The firm owned 12,958 shares of the medical equipment provider’s stock after selling 8,778 shares during the quarter. Teacher Retirement System of Texas’ holdings in Lantheus were worth $665,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Lantheus in the second quarter worth approximately $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus in the second quarter worth approximately $36,000. First Horizon Corp purchased a new position in shares of Lantheus during the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC grew its position in shares of Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares during the period. Finally, EMC Capital Management bought a new stake in shares of Lantheus during the 2nd quarter valued at $93,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Mizuho lifted their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial increased their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Trading Down 0.1%

LNTH stock opened at $65.93 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The business has a 50 day simple moving average of $65.35 and a two-hundred day simple moving average of $59.74. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of 27.70 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same quarter in the previous year, the firm earned $1.70 earnings per share. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.